Drug Discovery
Immunotherapy Screening

January 2015

To start off the year, take a moment to browse our special e-newsletter focused on popular pathways!

The treatment of diseases by inducing, enhancing, or surpressing an immune response is referred to as Immunotherapy. T-cell activation and inactivation requires the coordination of various co-inhibitory and co-stimulatory signals which are modulated by most immunotherapeutic approaches.
Take a look at a selection of posts by Dr Ali el Bayâ published on our blog Being Bioreactive, covering specific pathways in Drug Discovery.

PD-1/PD-L1/PD-L2 pathway

After a brief review of the role of this pathway in immune response, let’s take a look at some of the screening tools to investigate it for drug discovery applications. Interestingly, some of these tools are the first ready-to-use assay kits made available for drug discoverers to screen for inhibitors of the PD-1/PD-L1/PD-L2 pathway... [Read more...]

B7-1 / CD28 and B7-1 / CTLA4 pathways

In this post, our specialist describes the B7-1 : CD28 and B7-1 : CTLA4 pathways and summarizes the portfolio of tools currently available to researchers to investigate these pathways. In fact, these are the first kits on the market to screen for inhibitors of these pathways.[Read more...]

BLTA:HVEM and CD47:SIRPα pathways

Dr el Bayâ takes a look at the BLTA:HVEM and CD47:SIRPα pathways as well as a selection of screening tools from BPS Biosciences to investigate these pathways in drug discovery activities, and especially in inhibitor screenings. [Read more...]

GITR:GITRL pathway

The GITR:GITRL pathway is a very important target for immunotherapy drug discovery — in fact, the National Cancer Institute (USA) identified GITR modulation as one of the top 25 most promising research areas! Using anti-GITR mAb to trigger GITR signaling is effective in treating viral, bacterial, and parasitic infections, as well in boosting immune response against tumors...[Read more...]

CD40:CD40L pathway

The CD40:CD40L pathway is another highly studied, co-stimulatory pathway that affects both humoral and cell-mediated immunity. CD40 is constitutively expressed on B-cells, macrophages, and dendritic cells (DC), while CD40L (also known as CD154), is primarily expressed on T-helper cells shortly after activation (although it has also been found on other immune effector cells)...[Read more...]

CD137:CD137L pathway

CD137 is another co-stimulatory protein that is expressed on activated T cells. Unlike CD40:CD40L signaling, which primarily involves helper T-cells, CD137 has a crucial role in the development of cytotoxic T-cells and anti-tumor immunity. Its ligand, CD137L, is mainly expressed on antigen-presenting cells, such as activated B cells, macrophages, and dendritic cells, as well as on human tumor cells....[Read more...]

Get the best of tebu-bio online!

Don't wait to explore our website, to fully benefit from everything tebu-bio brings you.
Find your reagents and services with our powerful search engine, order online, or get in in touch with one of our specialists straight away via our Live Chat function...
Take a tour today!

Our Quality Promise to you! 100% Satisfaction guaranteed, so you can get to work with peace of mind...

tebu-bio's newsletters cover many of your favourite research themes...

Follow us on Facebook Follow us on Twitter Follow us on LinkedIn Follow us on YouTube Google+ Google+